Associated Papers
Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis.
Salani F et al.
Esmo Open, 2025
Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples.
Paweletz CP et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Specific cancer types and prognosis in patients with variations in the KEAP1-NRF2 system: A retrospective cohort study.
Iwasaki T et al.
Cancer Science, 2024
Exploring Genomic Biomarkers for Pembrolizumab Response: A Real-World Approach and Patient Similarity Network Analysis Reveal DNA Response and Repair Gene Mutations as a Signature.
Filetti M et al.
Cancers, 2024
Prevalence and Associations of Co-occurrence of NFE2L2 Mutations and Chromosome 3q26 Amplification in Lung Cancer.
Liu J et al.
Global Medical Genetics, 2024
Multiregional analysis of combined hepatocellular-cholangiocarcinoma reveals histologic diversity and molecular clonality.
Na HY et al.
Histopathology, 2024
Nrf2, A Target for Precision Oncology in Cancer Prognosis and Treatment.
Ngo HKC et al.
Journal of Cancer Prevention, 2023
A Comprehensive Study of De Novo Mutations on the Protein-Protein Interaction Interfaces Provides New Insights into Developmental Delay.
Maharjan DT et al.
Biomolecules, 2022
Detection of oncogenic and clinically actionable mutations in cancer genomes critically depends on variant calling tools.
Garcia-Prieto CA et al.
Bioinformatics (oxford, England), 2022
NRF2 DLG Domain Mutations Identified in Japanese Liver Cancer Patients Affect the Transcriptional Activity in HCC Cell Lines.
Haque E et al.
International Journal of Molecular Sciences, 2021
Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix.
Takayanagi D et al.
Cancers, 2021
Trans-Ancestry Mutation Landscape of Hepatoblastoma Genomes in Children.
Liu J et al.
Frontiers in Oncology, 2021
A combined clinical and biological risk classification improves prediction of outcome in hepatoblastoma patients.
Cairo S et al.
European Journal of Cancer (oxford, England : 1990), 2020
Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Torrente L et al.
Redox Biology, 2020
A catalogue of somatic NRF2 gain-of-function mutations in cancer.
Kerins MJ et al.
Scientific Reports, 2018
Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
Temko D et al.
The Journal of Pathology, 2018
The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
Eichenmüller M et al.
Journal of Hepatology, 2014
Genomic structure and variation of nuclear factor (erythroid-derived 2)-like 2.
Cho HY
Oxidative Medicine and Cellular Longevity, 2013
MRP3 gene expression correlates with NRF2 mutations in lung squamous cell carcinomas.
Sasaki H et al.
Molecular Medicine Reports, 2012
Increased NRF2 gene (NFE2L2) copy number correlates with mutations in lung squamous cell carcinomas.
Sasaki H et al.
Molecular Medicine Reports, 2012